PL3411484T3 - Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego - Google Patents
Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowegoInfo
- Publication number
- PL3411484T3 PL3411484T3 PL17747935.9T PL17747935T PL3411484T3 PL 3411484 T3 PL3411484 T3 PL 3411484T3 PL 17747935 T PL17747935 T PL 17747935T PL 3411484 T3 PL3411484 T3 PL 3411484T3
- Authority
- PL
- Poland
- Prior art keywords
- adenosatellite
- virus
- complementary
- threaded
- injection
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 210000004556 brain Anatomy 0.000 title 1
- 239000012530 fluid Substances 0.000 title 1
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292157P | 2016-02-05 | 2016-02-05 | |
| PCT/US2017/014914 WO2017136202A1 (en) | 2016-02-05 | 2017-01-25 | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3411484T3 true PL3411484T3 (pl) | 2024-02-19 |
Family
ID=59500060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17747935.9T PL3411484T3 (pl) | 2016-02-05 | 2017-01-25 | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12070510B2 (pl) |
| EP (2) | EP3411484B1 (pl) |
| JP (4) | JP2019504888A (pl) |
| AU (1) | AU2017214283B2 (pl) |
| DK (1) | DK3411484T3 (pl) |
| ES (1) | ES2962860T3 (pl) |
| FI (1) | FI3411484T3 (pl) |
| HR (1) | HRP20231451T1 (pl) |
| HU (1) | HUE064408T2 (pl) |
| IL (2) | IL300254B2 (pl) |
| LT (1) | LT3411484T (pl) |
| PL (1) | PL3411484T3 (pl) |
| PT (1) | PT3411484T (pl) |
| SI (1) | SI3411484T1 (pl) |
| WO (1) | WO2017136202A1 (pl) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5879256B2 (ja) | 2009-05-02 | 2016-03-08 | ジェンザイム・コーポレーション | 神経変性障害のための遺伝子治療 |
| CN105377039A (zh) | 2013-05-15 | 2016-03-02 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CN119876138A (zh) | 2014-11-14 | 2025-04-25 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| HK1245326A1 (zh) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | 用於生产scaav的组合物和方法 |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| PL3411484T3 (pl) | 2016-02-05 | 2024-02-19 | Emory University | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego |
| IL305449B2 (en) | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Gene therapy for the treatment of mucocutaneous type ii diabetes |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| CN110139933B (zh) | 2016-11-09 | 2024-03-08 | 英特瑞克斯顿股份有限公司 | 共济蛋白表达构建体 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| BR112020006671A2 (pt) | 2017-10-03 | 2020-12-01 | Prevail Therapeutics, Inc. | terapias genéticas para distúrbios lisossômicos |
| KR102709597B1 (ko) | 2017-10-03 | 2024-09-26 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애를 위한 유전자 요법 |
| EP3692075A4 (en) | 2017-10-03 | 2022-02-09 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| CN111902164A (zh) | 2018-02-01 | 2020-11-06 | 同源药物公司 | 用于恢复pah基因功能的腺相关病毒组合物及其使用方法 |
| SG11202011296VA (en) | 2018-05-15 | 2020-12-30 | Voyager Therapeutics Inc | Compositions and methods for the treatment of parkinson's disease |
| IL280198B2 (en) * | 2018-07-18 | 2026-01-01 | Regenxbio Inc | Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus) |
| WO2020068990A1 (en) | 2018-09-26 | 2020-04-02 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN113438954A (zh) | 2018-10-01 | 2021-09-24 | 宾夕法尼亚州大学信托人 | 可用于治疗gm1神经节苷脂病的组合物 |
| CN113227126A (zh) * | 2018-11-26 | 2021-08-06 | 巴塞罗那自治大学 | 成纤维细胞生长因子21(fgf21)基因治疗 |
| KR20210124299A (ko) * | 2019-02-04 | 2021-10-14 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Cln6 폴리뉴클레오티드의 아데노-관련 바이러스 전달 |
| SG11202109736RA (en) * | 2019-03-21 | 2021-10-28 | Ptc Therapeutics Inc | Vector and method for treating angelman syndrome |
| PL3953377T3 (pl) | 2019-04-10 | 2026-02-16 | Prevail Therapeutics, Inc. | Terapie genowe zaburzeń lizosomalnych |
| CA3136117A1 (en) | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| MA55625A (fr) * | 2019-04-12 | 2022-02-16 | Encoded Therapeutics Inc | Compositions et méthodes d'administration de produits thérapeutiques |
| EP3953484A4 (en) * | 2019-04-12 | 2023-04-12 | University of Massachusetts | Aav-mediated gene therapy for maple syrup urine disease (msud) |
| EP4085143B1 (en) * | 2019-12-31 | 2025-08-13 | Swanbio Therapeutics Limited | Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn) |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| EP4171659A4 (en) * | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | BIFUNCTIONAL BRIDGE COMPOSITIONS FOR VIRAL TRANSDUCTION |
| EP4171658A4 (en) * | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | Modified viral compositions for viral transduction |
| KR20230128001A (ko) * | 2020-12-01 | 2023-09-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 엔젤만 증후군의 치료를 위한 조성물 및 이의 용도 |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| AU2022310356A1 (en) | 2021-07-14 | 2024-01-25 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US6110743A (en) | 1995-02-10 | 2000-08-29 | The Regents Of The University Of California | Development and use of human pancreatic cell lines |
| CA2265460A1 (en) | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| EP1082413B1 (en) | 1998-05-28 | 2008-07-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Aav5 vector and uses thereof |
| CA2349838C (en) | 1998-11-05 | 2011-06-07 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| ES2340230T3 (es) | 1998-11-10 | 2010-05-31 | University Of North Carolina At Chapel Hill | Vectores viricos y sus procedimientos de preparacion y administracion. |
| PT1916258E (pt) | 1999-08-09 | 2014-07-29 | Genzyme Corp | Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia |
| NZ522840A (en) | 2000-06-01 | 2004-12-24 | Univ North Carolina | A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together |
| US9056048B2 (en) * | 2001-08-16 | 2015-06-16 | The Trustees Of The University Of Pennsylvania | Synthesis and use of cationic steroids for anti-inflammatory drug therapy |
| AU2002360416A1 (en) * | 2001-11-21 | 2003-06-10 | Activbiotics, Inc. | Targeted therapeutics and uses thereof |
| DE602004030327D1 (de) | 2003-05-21 | 2011-01-13 | Genzyme Corp | Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind |
| CN1856576B (zh) | 2003-09-30 | 2011-05-04 | 宾夕法尼亚州立大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| EP2019143A1 (en) | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
| DK2242840T3 (da) | 2008-01-29 | 2019-10-21 | Applied Genetic Tech Corporation | Produktion af rekombinant adeno-associeret virus under anvendelse af bhk-celler i suspension |
| US8679837B2 (en) | 2009-04-02 | 2014-03-25 | University Of Florida Research Foundation, Inc. | Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors |
| US8692332B2 (en) | 2010-01-14 | 2014-04-08 | United Microelectronics Corp. | Strained-silicon transistor and method of making the same |
| DK2529020T3 (en) | 2010-01-28 | 2018-08-06 | Childrens Hospital Philadelphia | SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY |
| ES2685611T3 (es) | 2011-02-14 | 2018-10-10 | The Children's Hospital Of Philadelphia | Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo |
| WO2013190059A1 (en) * | 2012-06-21 | 2013-12-27 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
| AU2013296425B2 (en) * | 2012-08-01 | 2018-06-07 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| MX380973B (es) | 2013-05-01 | 2025-03-12 | Genzyme Corp | Composiciones y metodos para tratar la atrofia muscular espinal. |
| EP3245221A4 (en) * | 2015-01-16 | 2018-06-13 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
| PL3411484T3 (pl) | 2016-02-05 | 2024-02-19 | Emory University | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego |
-
2017
- 2017-01-25 PL PL17747935.9T patent/PL3411484T3/pl unknown
- 2017-01-25 US US16/075,122 patent/US12070510B2/en active Active
- 2017-01-25 DK DK17747935.9T patent/DK3411484T3/da active
- 2017-01-25 HU HUE17747935A patent/HUE064408T2/hu unknown
- 2017-01-25 EP EP17747935.9A patent/EP3411484B1/en active Active
- 2017-01-25 IL IL300254A patent/IL300254B2/en unknown
- 2017-01-25 SI SI201731434T patent/SI3411484T1/sl unknown
- 2017-01-25 LT LTEPPCT/US2017/014914T patent/LT3411484T/lt unknown
- 2017-01-25 AU AU2017214283A patent/AU2017214283B2/en active Active
- 2017-01-25 ES ES17747935T patent/ES2962860T3/es active Active
- 2017-01-25 FI FIEP17747935.9T patent/FI3411484T3/fi active
- 2017-01-25 JP JP2018560432A patent/JP2019504888A/ja not_active Withdrawn
- 2017-01-25 EP EP23194145.1A patent/EP4299079A3/en not_active Withdrawn
- 2017-01-25 HR HRP20231451TT patent/HRP20231451T1/hr unknown
- 2017-01-25 WO PCT/US2017/014914 patent/WO2017136202A1/en not_active Ceased
- 2017-01-25 PT PT177479359T patent/PT3411484T/pt unknown
-
2018
- 2018-08-02 IL IL260954A patent/IL260954B2/en unknown
-
2022
- 2022-04-22 JP JP2022070524A patent/JP2022101648A/ja active Pending
-
2023
- 2023-11-07 US US18/504,029 patent/US20240108761A1/en not_active Abandoned
-
2024
- 2024-04-03 JP JP2024059869A patent/JP2024084797A/ja active Pending
- 2024-07-12 US US18/771,234 patent/US20250135041A1/en active Pending
- 2024-12-26 JP JP2024230721A patent/JP2025041933A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024084797A (ja) | 2024-06-25 |
| IL260954A (pl) | 2018-09-20 |
| IL300254B2 (en) | 2025-06-01 |
| LT3411484T (lt) | 2023-11-27 |
| IL300254B1 (en) | 2025-02-01 |
| US20190038777A1 (en) | 2019-02-07 |
| IL260954B1 (en) | 2023-03-01 |
| AU2017214283B2 (en) | 2023-06-29 |
| AU2017214283A1 (en) | 2018-08-02 |
| US20250135041A1 (en) | 2025-05-01 |
| PT3411484T (pt) | 2023-11-17 |
| EP4299079A3 (en) | 2024-05-01 |
| EP3411484A1 (en) | 2018-12-12 |
| FI3411484T3 (fi) | 2023-11-15 |
| EP4299079A2 (en) | 2024-01-03 |
| IL260954B2 (en) | 2023-07-01 |
| WO2017136202A1 (en) | 2017-08-10 |
| US20240108761A1 (en) | 2024-04-04 |
| HRP20231451T1 (hr) | 2024-03-01 |
| JP2022101648A (ja) | 2022-07-06 |
| DK3411484T3 (da) | 2023-11-20 |
| HUE064408T2 (hu) | 2024-03-28 |
| SI3411484T1 (sl) | 2023-12-29 |
| CA3012653A1 (en) | 2017-08-10 |
| JP2025041933A (ja) | 2025-03-26 |
| US12070510B2 (en) | 2024-08-27 |
| EP3411484A4 (en) | 2019-08-07 |
| JP2019504888A (ja) | 2019-02-21 |
| ES2962860T3 (es) | 2024-03-21 |
| IL300254A (en) | 2023-03-01 |
| EP3411484B1 (en) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3411484T3 (pl) | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego | |
| PT3506909T (pt) | Análogos de 4¿-fosfato e oligonucleótidos compreendendo os mesmos | |
| IL269354A (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| EP3689215A4 (en) | REGIONAL ATTRIBUTE DETERMINATION | |
| EP3464313A4 (en) | MODIFIED NUCLEOTIDES 5 '-CYCLO-PHOSPHONATE | |
| EP3360554A4 (en) | AGGREGATE AGAINST HEPATITIS B VIRUS | |
| EP3430731A4 (en) | IUGW ARCHITECTURE | |
| MA46180A (fr) | Analogues de l'amyline | |
| MA45192A (fr) | Traitement d'association | |
| EP3592232A4 (en) | STEERABLE GUIDE CATHETER | |
| EP3426242A4 (en) | ICARIIN AND ICARITIN DERIVATIVES | |
| MA46717A (fr) | Variantes de l'endonucléase homing tcra | |
| MA43873A (fr) | Dspositif d'injection | |
| EP3378606A4 (en) | AUXILIARY SET | |
| EP3525841A4 (en) | MICRO DELIVERY DEVICE | |
| ITUB20153015A1 (it) | Dispositivo per l'infusione di fluidi | |
| FR3055905B1 (fr) | Methode de sexage precoce d'esturgeon | |
| EP3415524A4 (en) | INHIBITOR OF α-SYNNUCLEINE EXPRESSION | |
| EP3482698A4 (en) | HEMOSTATIC INSTRUMENT | |
| EP3431808A4 (en) | BUFFER STOPPER | |
| EP3322451A4 (en) | ELECTROCHEMICAL REDUCTION OR PREVENTING INFECTIONS | |
| EP3365793A4 (en) | AUTHORIZING I / O COMMANDS WITH I / O TOKENS | |
| EP3444345A4 (en) | MicroRNA-143 DERIVATIVE | |
| EP3433782A4 (en) | INTEGRATED INTERACTIVE APPLICATION SAFETY TESTING | |
| MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 |